Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York, New York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 3923

The number of tables: 0

The number of figures: 4

The number of eTables: 13

The number of eFigures: 4

Abstract

Background: Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders.

Methods: We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant genome-wide association studies and replicated in FinnGen.

Results: After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-0.08]) and lower risk of depression (odds ratio 0.83 [0.74-0.94]) and bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI. There was also suggestive evidence that genetically predicted lower BMI via GLP-1R activation was associated with lower risk of post-partum depression, attention deficit hyperactivity disorder, and substance use disorders, and that genetically predicted lower glycated hemoglobin (HbA1c) via GLP-1R activation was associated with higher risk of anorexia nervosa but lower risk of Tourette syndrome. These associations were stronger than the associations for genetically predicted lower BMI and lower HbA1c based on genome-wide variants. The posterior probabilities of a shared causal variant affecting both BMI and the outcome at *GLP1R* were 59.3% for the well-being spectrum, 3.8% for depression, and 45.9% for bipolar disorder.

Conclusions: GLP-1R activation was associated with better mental health well-being and

lower risk of depression and bipolar disorder beyond that expected from the reduction in BMI and HbA1c.

(Word count: 250)

Keywords: bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian randomization, mental health

Key messages

- This drug-target Mendelian randomization study showed that genetically predicted glucagon-like peptide-1 receptor (GLP-1R) activation was associated with better mental health well-being and lower risk of depression and bipolar disorder.
- The associations of genetically predicted GLP-1R activation with favorable mental health outcomes were beyond that expected from the reduction in body mass index (BMI) and glycated hemoglobin (HbA1c).
- This genetic evidence suggests repurposing opportunities of GLP-1R agonists for improving mental health.

65 **Introduction**

66 Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1]
67 Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of
68 GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal
69 afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting
70 central nervous systems could have psychiatric effects. For example, the combination of
71 phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn
72 from the market due to serious psychiatric adverse events.[8] In contrast, the combination of
73 naltrexone and bupropion improves depression,[9] smoking cessation,[10,11] and
74 methamphetamine use disorder.[12]
75
76 Following reports of suicidal ideation and self-injury in people using GLP-1R agonists,[13] the
77 European Medicines Agency and the US Food and Drug Administration have been monitoring
78 the psychiatric safety of GLP-1R agonists. To date, the available evidence does not suggest a
79 causal association of GLP-1R agonist use with suicidal thoughts and actions.[14,15] RCTs have
80 suggested that GLP-1R agonists moderately reduce depressive symptoms in people who are
81 overweight or obese[16] and in people with type 2 diabetes.[17] Animal,[18,19] observational,[20,21] and
82 genetic studies[22] suggest potential benefits of GLP-1R agonists in alcohol use disorder;
83 however, RCTs have yielded contradictory evidence showing benefits or null effects.[23,24]
84 Early-stage trials are on-going to investigate the efficacy of GLP-1R agonists in individuals
85 with mental illnesses[25] and substance use disorders.[26] A better understanding of the

86 association of GLP-1R activation, the intended target of GLP-1R agonists, with mental health
87 has implications for informing their psychiatric safety and potential repurposing
88 opportunities.
89
90 To address this gap, we used Mendelian randomization (MR), an instrumental variable
91 analysis with genetic instruments, to obtain less confounded estimates than conventional
92 observational studies.[27] Previous MR studies suggested no association of GLP-1R activation
93 with suicide risk,[28,29] consistent with an RCT.[16] We used MR to assess the associations of
94 GLP-1R activation with mental health outcomes including the well-being spectrum, mental
95 health disorders, and substance use disorders. We further investigated whether any
96 associations were explained by lowering body mass index (BMI) or lowering glycated
97 hemoglobin (HbA1c).
98

99 **Methods**

100 ***Study design***

101 MR relies on the instrumental variable assumptions of relevance (the genetic instruments
102 should be related to the exposure), independence (no common cause of the genetic
103 instruments and the outcome exists), and exclusion restriction (the genetic instruments should
104 be independent of the outcome given the exposure).[30] This MR study took advantage of the
105 largest relevant publicly available genome-wide association studies (GWASs) (eTable 1).

106 First, we assessed the associations of GLP-1R activation predicted by *GLP1R* variants with
107 mental health outcomes including the well-being spectrum, mental health disorders, and
108 substance use disorders. We compared these associations with the associations for lower BMI
109 and lower HbA1c predicted by genome-wide variants. Second, we performed colocalization
110 analyses to examine whether any associations found for GLP-1R activation were driven by a
111 shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R* gene.[31]
112 Where possible, we conducted sex-specific analyses, because women are more likely to have
113 depression than men,[32] but boys are more likely to develop neurodevelopmental disorders
114 than girls.[33]
115

116 ***Genetic instruments***

117 We selected genetic instruments for GLP-1R activation based on their associations with
118 downstream traits related to drug target effects (BMI and HbA1c), because this approach
119 reduces the risk of the variant-outcome association being lost or confounded by pleiotropic
120 effects.[34] We obtained genetic associations with BMI (N = 806,834) from a meta-analysis of
121 the UK Biobank and GIANT[35] and with HbA1c (N = 344,182) from a GWAS of the UK
122 Biobank.[36] We considered these two sets of instruments separately, because they might
123 represent distinct mechanisms.[37] For primary analyses, we extracted variants in or near (+-
124 1Mb) the *GLP1R* gene that were uncorrelated (r^2<0.001) and genome-wide significantly (p
125 value $<5\times10^{-8}$) associated with BMI to mimic BMI-related mechanisms. We used the same
126 approach based on their associations with HbA1c to select genetic variants mimicking

127 HbA1c-related mechanisms. For sensitivity analyses, we used a less stringent significance
128 threshold for instrument selection (p value < 1×10^{-5}). For comparison, we also extracted
129 genetic instruments for BMI and HbA1c from across the genome (genome-wide variants) that
130 were uncorrelated (r^2 <0.001) and genome-wide significantly (p value <5×10^{-8}) associated
131 with BMI and HbA1c, respectively.
132
133 We used coronary artery disease (CAD), the most common cardiovascular disease, and all-
134 cause mortality as positive control outcomes, because RCTs have shown that GLP-1R
135 agonists reduce cardiovascular events and death.[2,3] We obtained genetic associations with
136 CAD (181,522 cases/984,168 controls) from a meta-analysis of the CARDIoGRAMplusC4D
137 consortium and the UK Biobank.[40] We obtained genetic associations with parental mortality
138 (609,139 cases/403,101 controls), determined by parental attained age and their alive/dead
139 status, from a meta-analysis of the UK Biobank and LifeGen as a measure of all-cause
140 mortality,[41] because it has greater power than participant's mortality. We used skin color (N =
141 356,530) obtained from the UK Biobank[36] as a negative control outcome. We also queried the
142 genetic instruments for GLP-1R activation in the IEU OpenGWAS database to assess possible
143 pleiotropic effects (p value <1×10^{-5}).
144
145 ***Genetic associations with mental health outcomes***
146 We obtained sex-combined and sex-specific genetic associations with mental health outcomes
147 from the largest relevant publicly available GWASs.[36,42-56] Primary outcomes included the

148 well-being spectrum, mental health disorders (depression, bipolar disorder, post-traumatic
149 stress disorder (PTSD), schizophrenia, anorexia nervosa, attention deficit hyperactivity
150 disorder (ADHD), autism spectrum disorder, and Tourette's syndrome), and substance use
151 disorders. Secondary outcomes included four dimensions of mental health well-being (life
152 satisfaction, positive affect, neuroticism, and depressive symptoms) and subtypes of mental
153 health disorders (postpartum depression and bipolar disorder I and II) and substance use
154 disorders (cannabis use disorder and alcohol dependence). Secondary outcomes also included
155 the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol
156 consumption, and score for alcohol problems. We obtained genetic associations with relevant
157 outcomes from the FinnGen R12 for replication, where possible.[57] Genetic associations with
158 binary outcomes obtained using linear regression were transformed into odds ratio (OR) using
159 an established approximation.[58]
160

161 ***MR analysis***

162 We used the F-statistic to assess instrument strength, approximated by the square of SNP-
163 exposure association divided by the square of its standard error.[59] An F-statistic larger than 10
164 suggests weak instrument bias is unlikely. We aligned SNPs on the same allele for exposure
165 and outcome, and used proxy SNPs (r^2>0.8), where possible, when SNPs were not available
166 in the outcome GWAS. We calculated Wald estimates by dividing genetic association with
167 outcome by genetic association with exposure. We obtained MR estimates by meta-analyzing
168 Wald estimates using inverse variance weighting (IVW) with fixed effects for three SNPs or

169 fewer and random effects for four SNPs or more.[60] To assess the robustness of IVW estimates,
170 we conducted sensitivity analyses using the weighted median,[61] MR Egger,[62] and MR using
171 the robust adjusted profile score (MR-RAPS).[63] We used the Cochran's Q statistic[64] to test
172 heterogeneity in Wald estimates and the MR Egger intercept[62] to assess directional pleiotropy.
173 We used the Steiger filtering to identify the SNPs explaining more variance in the outcome
174 than in the exposure (p value < 0.05).[65] We conducted sensitivity analyses excluding the SNPs
175 identified to assess whether MR estimates were affected by reverse causation. We used a
176 Bonferroni-corrected significance level of α=0.05/10=0.005 given ten primary outcomes. We
177 considered nominally significant associations (p value <0.05) that did not reach Bonferroni-
178 corrected significance as suggestive evidence. We tested differences by sex using a two-sided
179 z-test.[66]
180

181 ***Colocalization***

182 We performed pairwise colocalization analyses in a Bayesian framework to assess whether
183 any associations found for GLP-1R activation were driven by a shared causal variant affecting
184 both BMI or HbA1c and the outcome or were confounded by linkage disequilibrium.[31] We
185 included variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set
186 the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI or
187 HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant associated with
188 both traits.[31] We assessed the posterior probability of several hypotheses, including H_0 (no
189 association with either trait), H_1, (association with BMI or HbA1c only); H_2, (association with

the outcome only); H_3, (associations of two independent variants and one for each trait); H_4 (associations of one shared variant with both traits).[31] A posterior probability of H_4 larger than 0.80 suggests colocalization.[31] The power to detect colocalization is low when the variants are not strongly associated with the outcome, so we also calculated the posterior probability of colocalization (H_4) conditional on the presence of a variant associated with the outcome as $H_4/(H_2 + H_3 + H_4)$.[67] We reported the posterior probabilities of H_0-H_4 and conditional H_4 and the variant with the largest posterior probability of being the shared causal variant.

We also used the Hypothesis Prioritisation for multi-trait Colocalization (HyPrColoc)[68] to assess colocalization across multiple traits identified for GLP-1R activation. We set the prior probability for a variant associated with at least one trait as 10^{-4} and the conditional prior probability for a variant associated with an additional trait given that the variant is associated with at least one other trait as 0.02.[68] We reported clusters of putatively colocalized traits and the posterior probability of colocalization.

All statistical analyses were conducted using R version 4.2.1 and the packages “ieugwasr”, “TwoSampleMR”, “MendelianRandomization”, “mr.raps, “metafor”, “coloc”, and “hyprcoloc”.

209 **Results**

210 ***Genetic instruments***

211 For primary analyses, we used two *GLP1R* SNPs (rs17757975 and rs4714290) genome-wide
212 significantly associated with BMI to predict the impact of GLP-1R activation as indicated by
213 lower BMI; we used one *GLP1R* SNP (rs10305518) genome-wide significantly associated
214 with HbA1c to predict the impact of GLP-1R activation as indicated by lower HbA1c (eTable
215 2). For sensitivity analyses, we used three *GLP1R* SNPs for BMI and two *GLP1R* SNPs for
216 HbA1c based on a more lenient significance threshold (p value $< 1\times10^{-5}$) (eTable 2). Beyond
217 BMI and HbA1c, some of these genetic instruments were associated with body composition,
218 body impedance, basal metabolic rate, atrial fibrillation, age at menarche, gastroesophageal
219 reflux disease, or area of the left inferior temporal region (p value $< 1\times10^{-5}$) (eTable 3). The
220 *GLP1R* SNPs for BMI were not associated with HbA1c and vice versa (eTable 4), which
221 substantiated that the two sets of genetic instruments represent distinct mechanisms of GLP-
222 1R activation.[37] For comparison, we also extracted 516 (overall), 303 (women), and 256
223 (men) SNPs for BMI and 318 (overall), 200 (women), 174 (men) SNPs for HbA1c from
224 across the genome (eTable 5). The F-statistics of the primary instruments were all >10
225 (eTables 2 and 5).

226

227 In positive control analyses, genetically predicted lower BMI and lower HbA1c via GLP-1R
228 activation were associated with lower CAD risk and all-cause mortality, despite wide
229 confidence intervals (CIs) (eFigure 1). The point estimates for genetically predicted lower

230 BMI and lower HbA1c via GLP-1R activation were comparable to those for genetically
231 predicted lower BMI and lower HbA1c based on genome-wide variants (eFigure 1 and eTable
232 6). In negative control analyses, genetically predicted lower BMI and lower HbA1c via GLP-
233 1R activation were not associated with skin color (eTable 7).
234

235 ***Associations of GLP-1R activation with mental health well-being***

236 Genetically predicted lower BMI via GLP-1R activation was associated with a better well-
237 being spectrum, including life satisfaction, positive affect, neuroticism, and depressive
238 symptoms (Figure 1). The associations with depressive symptoms were similar in women and
239 men (eFigure 2). These associations were stronger than the associations for genetically
240 predicted lower BMI using genome-wide variants (Figure 1). However, genetically predicted
241 lower HbA1c via GLP-1R activation had little association with mental health well-being
242 (Figure 1). The Cochran's Q statistics suggested heterogeneity; however, the MR Egger
243 intercept did not indicate directional pleiotropy and the weighted median, MR Egger, and
244 MR-RAPS gave consistent estimates (eTables 8-9). The Steiger filtering identified no SNP
245 that explained more variance in the outcome than in the exposure (eTable 8-9).
246

247 ***Associations of GLP-1R activation with the risk of mental health disorders***

248 Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of
249 depression, postpartum depression, bipolar disorder, bipolar disorder I and II, and ADHD

250 (Figure 2). The association with depression was possibly stronger in women (OR (95% CI)
251 0.75 (0.52 to 1.08)) than men (0.98 (0.65 to 1.47)), although the *p* value for sex difference
252 was 0.35 (eFigure 3). These associations were stronger than the associations for genetically
253 predicted lower BMI using genome-wide variants (Figure 2). Genetically predicted lower
254 HbA1c via GLP-1R activation was associated with higher risk of anorexia nervosa but lower
255 risk of Tourette syndrome, with stronger associations than the associations for genetically
256 predicted lower HbA1c using genome-wide variants (Figure 2). The MR Egger intercept
257 suggested some directional pleiotropy for genetically predicted lower BMI and lower HbA1c
258 using genome-wide variants (eTable 10). However, the results were similar when using
259 different MR methods and when excluding the SNPs explaining more variance in the outcome
260 than in the exposure identified by the Steiger filtering (eTable 10).
261

262 ***Associations of GLP-1R activation with the risk of substance use disorders***

263 Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of
264 substance use disorders and lower AUDIT score for alcohol problems, with stronger
265 associations than the associations for genetically predicted lower BMI using genome-wide
266 variants (Figure 3). However, genetically predicted lower HbA1c via GLP-1R activation had
267 little association with the risk of substance use disorders (Figure 3). The MR Egger intercept
268 suggested some directional pleiotropy for genetically predicted lower BMI and lower HbA1c
269 using genome-wide variants, but sensitivity analyses using different MR methods and
270 excluding the SNPs identified by the Steiger filtering gave similar interpretations (eTable 11).

271

272 ***Replication***

273 In FinnGen, genetically predicted lower BMI via GLP-1R activation was associated with
274 lower risk of depression, bipolar disorder, PTSD, ADHD, substance abuse, and alcohol
275 dependence (eFigure 4). These associations were stronger than those for genetically predicted
276 lower BMI using genome-wide variants (eFigure 4). Genetically predicted lower HbA1c via
277 GLP-1R activation had little association with mental health outcomes except for depression
278 (eFigure 4). Nevertheless, this association was attenuated to null when using the two SNPs
279 extracted based on a more lenient significance threshold (eTable 12).

280

281 ***Colocalization***

282 After correcting for multiple comparisons, genetically predicted lower BMI via GLP-1R
283 activation remained significantly associated with the well-being spectrum, life satisfaction,
284 positive affect, neuroticism, depressive symptoms, depression, bipolar disorder, and bipolar
285 disorder I (p values <0.005). Pairwise colocalization analyses were performed for BMI and
286 each significant outcome in or near the *GLP1R* gene. The posterior probabilities of
287 colocalization were <80% for all the significant outcomes (Figure 4). However, conditioning
288 on the presence of a variant associated with the outcome, the posterior probabilities of
289 colocalization were all >80% except for depression (Figure 4), suggesting that some lack of
290 colocalization was due to limited power. The posterior probabilities of two independent

291 variants associated with each trait were <15% for all the significant outcomes (eTable 13),
292 suggesting that confounding by linkage disequilibrium was unlikely. Across the *GLP1R* gene
293 region, rs4714290, rs847784 (a proxy for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest
294 posterior probability of being the shared causal variant, which substantiated their validity as
295 genetic instruments.
296
297 Multi-trait colocalization analyses were performed across BMI and all the significant
298 outcomes in or near the *GLP1R* gene. We identified BMI, the well-being spectrum, life
299 satisfaction, positive affect, neuroticism, depressive symptoms as a cluster of putatively
300 colocalized traits with the posterior probability of colocalization 51.9%.
301

302 **Discussion**

303 Consistent with some RCTs,[16,17] this MR study suggests that GLP-1R activation is associated
304 with lower risk of depression. We build on the evidence base by showing that GLP-1R
305 activation is associated with a better well-being spectrum and lower risk of bipolar disorder.
306 We also provide suggestive evidence that GLP-1R activation is associated with lower risk of
307 postpartum depression, ADHD, Tourette syndrome, and substance use disorders but higher
308 risk of anorexia nervosa. These associations were stronger than those expected from the
309 reduction in BMI and HbA1c.
310

311 Our investigations suggest that GLP-1R activation is associated with a better well-being
312 spectrum and lower risk of depression and bipolar disorder. Consistently, RCTs have shown
313 that GLP-1R agonists moderately reduce depression symptoms in overweight people[16] and in
314 people with type 2 diabetes.[17] A small open-label trial showed that liraglutide, as an adjunct to
315 existing pharmacotherapy, improved cognitive function[69] and brain volumes[70] in people with
316 depression or bipolar disorder. GLP-1 has neuroprotective effects including enhanced
317 neurogenesis, improved barrier function, reduced neuroinflammation, and decreased oxidative
318 stress.[71] These effects might contribute to the psychiatric benefits of GLP-1R activation and
319 are consistent with RCTs showing that GLP-1R agonists improve neurodegenerative diseases,
320 such as Parkinson's disease.[72,73]
321
322 Interestingly, the associations of GLP-1R activation with mental health well-being,
323 depression, and bipolar disorder were evident when instrumenting on BMI but not on HbA1c,
324 suggesting the relevance of BMI-related mechanisms. A recent study showed that GLP-1R
325 agonists target the hindbrain dorsal vagal complex to decrease food intake and body weight.[4]
326 Actions on the hypothalamus and vagal afferents also contribute to the weight loss on GLP-
327 1R agonists.[5,6] GLP neurons in the dorsal vagal complex moderate stress responses and
328 stimulate hypothalamic-pituitary-adrenal (HPA) axis activity, which has been implicated in
329 the pathology of depression[74] and bipolar disorder.[75] Notably, the HPA axis is also related to
330 cognitive function,[74,75] consistent with an RCT showing that dulaglutide reduces cognitive
331 impairment in people with type 2 diabetes.[76] Additional studies are warranted to elucidate the

332 mechanisms underlying potential benefits of GLP-1R agonists for mental health.

333

334 We found that GLP-1R activation was possibly associated with lower risk of depression more
335 in women than men and was associated with lower risk of postpartum depression. We caution
336 that the power to detect sex differences may have been limited by small or unequal sample
337 sizes of sex-stratified GWAS. Women are about twice as likely as men to have depression
338 during their lifetime with the difference starting at puberty.[32] A meta-analysis of RCTs showed
339 that GLP-1R agonists decreased testosterone and increased sex hormone-binding globulin in
340 women with polycystic ovary syndrome,[77] but their effects on estrogen are less clear. Sex
341 hormones might contribute to GLP-1R activation improving depression in women, given their
342 potential roles in modulating serotonergic neurotransmission, cortisol, and oxytocin.[78]

343

344 GLP-1R activation was not associated with higher risk of neurodevelopmental disorders
345 including ADHD, autism spectrum disorder, and Tourette syndrome. Although RCTs have
346 showed the short-term (no more than 26 weeks) safety of GLP-1R agonists in children and
347 adolescents,[79] RCTs typically do not capture the long latency of neurodevelopmental
348 disorders. Our study adds to the evidence by showing little adverse effect of lifelong GLP-1R
349 activation on these disorders. However, GLP-1R activation was possibly associated with
350 higher risk of anorexia nervosa when instrumenting on HbA1c. GLP-1R activation increases
351 insulin secretion and sensitivity and lowers glucose.[80] A previous MR study suggested an
352 inverse association of fasting insulin with the risk of anorexia nervosa,[81] indicating a role of

353 insulin sensitivity.

354

355 We provide suggestive evidence that GLP-1R activation is associated with lower risk of
356 substance use disorders and lower AUDIT score for alcohol problems. Although the benefits
357 of GLP-1R activation on substance abuse and alcohol dependence were replicated in
358 FinnGen, this evidence should be treated with caution. A recent RCT showed that eight-week
359 treatment with semaglutide reduced alcohol consumption and craving in people with alcohol
360 use disorder.[24] In contrast, another RCT including people with alcohol use disorder showed
361 that 26 weeks of treatment with exenatide did not significantly reduce heavy drinking days,
362 although exenatide attenuated fMRI alcohol cue reactivity in brain areas for drug reward and
363 addiction.[23] Further evidence from RCTs is needed to determine the repurposing opportunities
364 of GLP-1R agonists for treating substance use disorders.

365

366 We presented the MR estimates of GLP-1R activation in effect sizes of BMI or HbA1c
367 reduction for interpretability. However, this scaling does not imply that weight loss or glucose
368 lowering is the sole mechanism of action for the psychiatric effects of GLP-1R activation.
369 Indeed, the associations of GLP-1R activation with mental health outcomes exceeded those
370 expected from lowering BMI and HbA1c. Correspondingly, RCTs have showed that
371 semaglutide reduces cardiovascular events and mortality more than expected from the
372 reduction in body weight,[16] and that GLP-1R agonists outperform other anti-diabetes drugs.[82]
373 Apart from reducing body weight and glucose, GLP-1R agonists also decrease blood pressure,

374 low-density lipoprotein cholesterol, and inflammation and enhance kidney function.[2,3] We
375 extend the evidence by suggesting that GLP-1R activation is associated with better mental
376 health beyond that expected from the reduction in BMI and HbA1c, which may also
377 contribute to the cardiovascular and mortality benefits of GLP-1R agonists.[83] A parsimonious
378 model explaining the multifaceted effects of GLP-1R agonists would be helpful. For example,
379 GLP-1R agonists activating 5' adenosine monophosphate-activated protein kinase
380 (AMPK)[84,85] can explain several aspects of their benefits, given the central role of AMPK in
381 metabolism across tissues including the brain.[86]
382
383 This is the first drug-target MR study comprehensively exploring the associations of GLP-1R
384 activation with mental health outcomes. The finding that GLP-1R activation is associated with
385 better mental health well-being and lower risk of bipolar disorder is novel. Our investigation
386 also has implications for the use of GLP-1R agonists in people with mental health disorders,
387 who usually have higher risk of obesity and type 2 diabetes but are undertreated. This study
388 has several limitations. First, MR relies on three rigorous assumptions, that is genetic
389 instruments should be related to the exposure, share no common cause with the outcome, and
390 be independent of the outcome given the exposure.[30] The F-statistics were >10, suggesting
391 minimal weak instrument bias. We validated the genetic instruments using CAD and all-cause
392 mortality as positive control outcomes. We used MR methods with different assumptions
393 about instrumental validity, which gave consistent estimates. Second, we selected genetic
394 instruments for GLP-1R activation based on their associations with BMI and HbA1c, but

395 additional underlying factors may explain their psychiatric effects. Instrumenting on BMI and
396 HbA1c could have masked some effects of GLP-1R activation. Third, the small number of
397 genetic instruments for GLP-1R activation, even when applying a more lenient significance
398 threshold for instrument selection, may have limited the detection of possible causal effects or
399 directional pleiotropy. Fourth, we obtained genetic associations with BMI from a meta-
400 analysis of the UK Biobank and GIANT and with HbA1c from the UK Biobank, which
401 overlaps with some outcome GWASs. Two-sample MR methods in a one-sample setting
402 perform well in terms of bias and precision in large biobanks, except for MR Egger which can
403 result in bias reflecting the direction and magnitude of confounding.[87] We replicated the
404 results using outcome GWASs from FinnGen, which has no overlap with the UK Biobank or
405 GIANT. Fifth, the power to detect colocalization was insufficient. However, the posterior
406 probabilities of two independent variants associated with each trait were <15% for all the
407 significant outcomes, suggesting that the associations found were unlikely driven by
408 confounding due to linkage disequilibrium. Sixth, MR can be open to selection bias from
409 selecting on genetic makeup and mental health disorders. Nevertheless, such selection should
410 bias towards a harmful effect of GLP-1R activation, which does not explain its associations
411 with lower risk of depression and bipolar disorder. Seventh, we obtained genetic associations
412 with mental health disorders from GWAS meta-analyses where outcome definitions may vary
413 across studies. Also, mental health disorders sometimes originate during childhood or
414 adolescence, but GLP-1R agonists are primarily used in adults. Our MR study assessed
415 lifelong effects of GLP-1R activation on mental health, which cannot directly inform the

416 short-term effects of GLP-1R agonists. The efficacy of GLP-1R agonists can also depend on
417 their pharmacological properties, the population treated, and the timing of treatment. RCTs
418 are warranted to determine the clinical relevance of these findings in the future.
419

420 **Conclusions**

421 This drug-target MR study provides genetic evidence that GLP-1R activation is associated
422 with better mental health well-being and lower risk of depression and bipolar disorder beyond
423 that expected from the reduction in BMI and HbA1c.
424

425 **List of abbreviations**

426 ADHD, attention deficit hyperactivity disorder
427 AMPK, 5' adenosine monophosphate-activated protein kinase
428 AUDIT, Alcohol Use Disorders Identification Test
429 BMI, body mass index
430 CAD, coronary artery disease
431 GLP-1R, glucagon-like peptide-1 receptor
432 GWAS, genome-wide association studies
433 HbA1c, glycated hemoglobin
434 HPA, hypothalamic-pituitary-adrenal

HyPrColoc, Hypothesis Prioritisation for multi-trait Colocalization

IVW, inverse variance weighting

MR, Mendelian randomization

OR, odds ratio

PTSD, post-traumatic stress disorder

RAPS, robust adjusted profile score

RCT, randomized controlled trials

Declarations

Ethics approval and consent to participate

All the analyses were conducted using publicly available summary statistics, which does not require ethical approval. Participants of the original studies of publicly available summary statistics provided informed consent.

Availability of data and materials

Summary statistics analyzed are available in the website https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/ for HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD, https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality,

https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being, and https://pgc.unc.edu/for-researchers/download-results/ and https://www.finngen.fi/en/access_results for mental health disorders and substance use disorders.

Competing interests

The authors declared no conflict of interest.

Funding

SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). The funders had no role in the study design, analyses, or interpretation of results.

Author contributions

GY and CMS designed the study. GY undertook analyses with feedback from SB and CMS. GY drafted the manuscript with critical feedback and revisions from SB and CMS. All authors read and approved the final version of the manuscript. GY had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data

analysis.

Acknowledgements

The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D Consortium, Timmers PR, et al., Baselmans BML, et al., the Psychiatric Genomics Consortium, and FinnGen for their publicly available summary data.

Artificial intelligence (AI)-assisted technologies

The authors declared that AI-assisted technologies were not used in this study.

481 **References**

482 1. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease.
483 *Nature reviews Endocrinology*. Jul 2018;14(7):390-403. doi:10.1038/s41574-018-0016-2
484 2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular
485 Outcomes in Obesity without Diabetes. *N Engl J Med*. Dec 14 2023;389(24):2221-2232.
486 doi:10.1056/NEJMoa2307563
487 3. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes
488 with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-
489 analysis of randomised trials. *Lancet Diabetes Endocrinol*. Oct 2021;9(10):653-662.
490 doi:10.1016/s2213-8587(21)00203-5
491 4. Huang KP, Acosta AA, Ghidewon MY, et al. Dissociable hindbrain GLP1R circuits for
492 satiety and aversion. *Nature*. Jul 10 2024;doi:10.1038/s41586-024-07685-6
493 5. Burmeister MA, Ayala JE, Smouse H, et al. The Hypothalamic Glucagon-Like Peptide 1
494 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose
495 Homeostasis in Mice. *Diabetes*. Feb 2017;66(2):372-384. doi:10.2337/db16-1102
496 6. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-
497 1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. *Diabetes*. Jan
498 2016;65(1):34-43. doi:10.2337/db15-0973
499 7. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release,
500 phentermine plus topiramate combination on weight and associated comorbidities in
501 overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

502 *Lancet (London, England)*. Apr 16 2011;377(9774):1341-52. doi:10.1016/s0140-
503 6736(11)60205-5
504 8. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular
505 events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet (London,*
506 *England)*. Aug 14 2010;376(9740):517-23. doi:10.1016/s0140-6736(10)60935-x
507 9. Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL.
508 Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion
509 combination therapy: a pooled analysis. *International journal of obesity (2005)*. Oct
510 2019;43(10):2085-2094. doi:10.1038/s41366-018-0302-z
511 10. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and
512 placebo for smoking cessation. *The New England journal of medicine*. Oct 23
513 1997;337(17):1195-202. doi:10.1056/nejm199710233371703
514 11. Mooney ME, Schmitz JM, Allen S, et al. Bupropion and naltrexone for smoking
515 cessation: A double-blind randomized placebo-controlled clinical trial. *Clinical pharmacology*
516 *and therapeutics*. Oct 2016;100(4):344-52. doi:10.1002/cpt.402
517 12. Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine
518 Use Disorder. *The New England journal of medicine*. Jan 14 2021;384(2):140-153.
519 doi:10.1056/NEJMoa2020214
520 13. European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor
521 agonists. Accessed September 20, 2024. https://www.ema.europa.eu/en/news/ema-statement-
522 ongoing-review-glp-1-receptor-agonists

523 14. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk
524 Assessment Committee (PRAC) 8-11 April 2024. Accessed September 20, 2024.
525 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-
526 committee-prac-8-11-april-2024
527 15. US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of
528 suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2
529 diabetes and obesity. Accessed September 20, 2024. https://www.fda.gov/drugs/drug-safety-
530 and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-
531 taking-certain-type
532 16. Wadden TA, Brown GK, Egebjerg C, et al. Psychiatric Safety of Semaglutide for Weight
533 Management in People Without Known Major Psychopathology: Post Hoc Analysis of the
534 STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine*. Sep 3
535 2024;doi:10.1001/jamainternmed.2024.4346
536 17. Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1 Receptor
537 Agonists: A Systematic Review and Meta-Analysis. *The American journal of geriatric*
538 *psychiatry : official journal of the American Association for Geriatric Psychiatry*. Jan
539 2024;32(1):117-127. doi:10.1016/j.jagp.2023.08.010
540 18. Suchankova P, Yan J, Schwandt ML, et al. The glucagon-like peptide-1 receptor as a
541 potential treatment target in alcohol use disorder: evidence from human genetic association
542 studies and a mouse model of alcohol dependence. *Translational psychiatry*. Jun 16
543 2015;5(6):e583. doi:10.1038/tp.2015.68

19. Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. *EBioMedicine*. Jul 2023;93:104642. doi:10.1016/j.ebiom.2023.104642

20. Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jørgensen MB, Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. *Basic & clinical pharmacology & toxicology*. Nov 2022;131(5):372-379. doi:10.1111/bcpt.13776

21. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. *Nature communications*. May 28 2024;15(1):4548. doi:10.1038/s41467-024-48780-6

22. Reitz J, Rosoff DB, Perlstein T, et al. Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study. *Mol Psychiatry*. Sep 10 2025;doi:10.1038/s41380-025-03199-3

23. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. *JCI insight*. Oct 10 2022;7(19)doi:10.1172/jci.insight.159863

24. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. Apr 1 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789

25. Ganeshalingam AA, Uhrenholt NG, Arnfred S, Gæde PH, Bilenberg N, Frystyk J. Home-

565 based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes
566 (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-
567 blinded multicentre trial. *BMJ open*. Mar 18 2024;14(3):e077173. doi:10.1136/bmjopen-2023-
568 077173
569 26. Köhne S, Hillemacher T, Glahn A, Bach P. Emerging drugs in phase II and III clinical
570 development for the treatment of alcohol use disorder. *Expert opinion on emerging drugs*. Sep
571 2024;29(3):219-232. doi:10.1080/14728214.2024.2342951
572 27. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian
573 randomization: using genes as instruments for making causal inferences in epidemiology.
574 *Statistics in medicine*. Apr 15 2008;27(8):1133-63. doi:10.1002/sim.3034
575 28. Zhao SS, Burgess S, Gill D. Glucagon-Like Peptide-1 Receptor Agonism and Suicide
576 Risk: Evidence From Mendelian Randomization. *Journal of the American Heart Association*.
577 Jun 18 2024;13(12):e035948. doi:10.1161/jaha.124.035948
578 29. Nguyen A, Smith E, Hashemy H, et al. Glucagon-like-peptide 1 receptor agonism and
579 attempted suicide: A Mendelian randomisation study to assess a potential causal association.
580 *Clinical obesity*. Aug 2024;14(4):e12676. doi:10.1111/cob.12676
581 30. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to
582 causal inference. *Statistical methods in medical research*. Aug 2007;16(4):309-30.
583 doi:10.1177/0962280206077743
584 31. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation
585 between pairs of genetic association studies using summary statistics. *PLoS genetics*. May

586 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383

587 32. Kuehner C. Why is depression more common among women than among men? *The*

588 *lancet Psychiatry*. Feb 2017;4(2):146-158. doi:10.1016/s2215-0366(16)30263-2

589 33. Bölte S, Neufeld J, Marschik PB, Williams ZJ, Gallagher L, Lai MC. Sex and gender in

590 neurodevelopmental conditions. *Nature reviews Neurology*. Mar 2023;19(3):136-159.

591 doi:10.1038/s41582-023-00774-6

592 34. Gill D, Dib MJ, Cronjé HT, et al. Common pitfalls in drug target Mendelian

593 randomization and how to avoid them. *BMC Med*. Oct 15 2024;22(1):473.

594 doi:10.1186/s12916-024-03700-9

595 35. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new

596 insights for obesity biology. *Nature*. Feb 12 2015;518(7538):197-206.

597 doi:10.1038/nature14177

598 36. UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.

599 37. Patel A, Gill D, Shungin D, et al. Robust use of phenotypic heterogeneity at drug target

600 genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to

601 GLP1R gene region. *Genetic epidemiology*. Jun 2024;48(4):151-163. doi:10.1002/gepi.22551

602 38. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. May

603 2007;132(6):2131-57. doi:10.1053/j.gastro.2007.03.054

604 39. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*.

605 Sep 11 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776

606 40. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk

607 variants and genes for coronary artery disease in over a million participants. *Nat Genet*. Dec
608 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
609 41. Timmers PR, Mounier N, Lall K, et al. Genomics of 1 million parent lifespans implicates
610 novel pathways and common diseases and distinguishes survival chances. *eLife*. Jan 15
611 2019;8doi:10.7554/eLife.39856
612 42. Baselmans BML, Jansen R, Ip HF, et al. Multivariate genome-wide analyses of the well-
613 being spectrum. *Nature genetics*. Mar 2019;51(3):445-451. doi:10.1038/s41588-018-0320-8
614 43. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression
615 identifies 102 independent variants and highlights the importance of the prefrontal brain
616 regions. *Nature neuroscience*. Mar 2019;22(3):343-352. doi:10.1038/s41593-018-0326-7
617 44. Guintivano J, Byrne EM, Kiewa J, et al. Meta-Analyses of Genome-Wide Association
618 Studies for Postpartum Depression. *The American journal of psychiatry*. Dec 1
619 2023;180(12):884-895. doi:10.1176/appi.ajp.20230053
620 45. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more
621 than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nature*
622 *genetics*. Jun 2021;53(6):817-829. doi:10.1038/s41588-021-00857-4
623 46. Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD
624 genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. *Nature*
625 *communications*. Oct 8 2019;10(1):4558. doi:10.1038/s41467-019-12576-w
626 47. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and
627 synaptic biology in schizophrenia. *Nature*. Apr 2022;604(7906):502-508.

628 doi:10.1038/s41586-022-04434-5

629 48. Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies

630 eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature*

631 *genetics*. Aug 2019;51(8):1207-1214. doi:10.1038/s41588-019-0439-2

632 49. Demontis D, Walters GB, Athanasiadis G, et al. Genome-wide analyses of ADHD

633 identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains.

634 *Nature genetics*. Feb 2023;55(2):198-208. doi:10.1038/s41588-022-01285-8

635 50. Martin J, Walters RK, Demontis D, et al. A Genetic Investigation of Sex Bias in the

636 Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biological psychiatry*. Jun 15

637 2018;83(12):1044-1053. doi:10.1016/j.biopsych.2017.11.026

638 51. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism

639 spectrum disorder. *Nature genetics*. Mar 2019;51(3):431-444. doi:10.1038/s41588-019-0344-

640 8

641 52. Yu D, Sul JH, Tsetsos F, et al. Interrogating the Genetic Determinants of Tourette's

642 Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *The*

643 *American journal of psychiatry*. Mar 1 2019;176(3):217-227.

644 doi:10.1176/appi.ajp.2018.18070857

645 53. Hatoum AS, Colbert SMC, Johnson EC, et al. Multivariate genome-wide association

646 meta-analysis of over 1 million subjects identifies loci underlying multiple substance use

647 disorders. *Nature Mental health*. Mar 2023;1(3):210-223. doi:10.1038/s44220-023-00034-y

648 54. Johnson EC, Demontis D, Thorgeirsson TE, et al. A large-scale genome-wide association

study meta-analysis of cannabis use disorder. *The lancet Psychiatry*. Dec 2020;7(12):1032-1045. doi:10.1016/s2215-0366(20)30339-4

55. Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nature neuroscience*. Dec 2018;21(12):1656-1669. doi:10.1038/s41593-018-0275-1

56. Sanchez-Roige S, Palmer AA, Fontanillas P, et al. Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *The American journal of psychiatry*. Feb 1 2019;176(2):107-118. doi:10.1176/appi.ajp.2018.18040369

57. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*. Jan 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8

58. Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio. *Genetics*. Apr 2018;208(4):1397-1408. doi:10.1534/genetics.117.300360

59. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol*. Dec 1 2016;45(6):1961-1974. doi:10.1093/ije/dyw220

60. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. Nov 2013;37(7):658-65.

670 doi:10.1002/gepi.21758

671 61. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
672 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic*
673 *epidemiology*. May 2016;40(4):304-14. doi:10.1002/gepi.21965

674 62. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
675 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*.
676 Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080

677 63. Qingyuan Z, Jingshu W, Gibran H, Jack B, Dylan SS. Statistical inference in two-sample
678 summary-data Mendelian randomization using robust adjusted profile score. *The Annals of*
679 *Statistics*. 6/1 2020;48(3):1742-1769. doi:10.1214/19-AOS1866

680 64. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
681 randomisation studies with summary data and a continuous outcome. *Stat Med*. Sep 20
682 2015;34(21):2926-40. doi:10.1002/sim.6522

683 65. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
684 imprecisely measured traits using GWAS summary data. *PLoS genetics*. Nov
685 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081

686 66. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*
687 *(Clinical research ed)*. Jan 25 2003;326(7382):219. doi:10.1136/bmj.326.7382.219

688 67. Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization
689 and colocalization: Review and comparison of approaches. *American journal of human*
690 *genetics*. May 5 2022;109(5):767-782. doi:10.1016/j.ajhg.2022.04.001

691 68. Foley CN, Staley JR, Breen PG, et al. A fast and efficient colocalization algorithm for
692 identifying shared genetic risk factors across multiple traits. *Nat Commun*. Feb 3
693 2021;12(1):764. doi:10.1038/s41467-020-20885-8
694 69. Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective
695 measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label
696 study. *Journal of affective disorders*. Jan 1 2017;207:114-120. doi:10.1016/j.jad.2016.09.056
697 70. Mansur RB, Zugman A, Ahmed J, et al. Treatment with a GLP-1R agonist over four
698 weeks promotes weight loss-moderated changes in frontal-striatal brain structures in
699 individuals with mood disorders. *European neuropsychopharmacology : the journal of the*
700 *European College of Neuropsychopharmacology*. Nov 2017;27(11):1153-1162.
701 doi:10.1016/j.euroneuro.2017.08.433
702 71. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of
703 GIP and GLP1. *Nature reviews Endocrinology*. Apr 2023;19(4):201-216. doi:10.1038/s41574-
704 022-00783-3
705 72. Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in Early Parkinson's
706 Disease. *The New England journal of medicine*. Apr 4 2024;390(13):1176-1185.
707 doi:10.1056/NEJMoa2312323
708 73. McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01
709 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
710 *The Lancet Neurology*. Jan 2024;23(1):37-45. doi:10.1016/s1474-4422(23)00378-2
711 74. Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical

712 symptomatology and genetic variation predict cognition. *Molecular psychiatry*. Apr
713 2017;22(4):527-536. doi:10.1038/mp.2016.120
714 75. Belvederi Murri M, Prestia D, Mondelli V, et al. The HPA axis in bipolar disorder:
715 Systematic review and meta-analysis. *Psychoneuroendocrinology*. Jan 2016;63:327-42.
716 doi:10.1016/j.psyneuen.2015.10.014
717 76. Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive
718 impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. *The Lancet*
719 *Neurology*. Jul 2020;19(7):582-590. doi:10.1016/s1474-4422(20)30173-3
720 77. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual
721 cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.
722 *BMC endocrine disorders*. Nov 8 2023;23(1):245. doi:10.1186/s12902-023-01500-5
723 78. Martel MM. Sexual selection and sex differences in the prevalence of childhood
724 externalizing and adolescent internalizing disorders. *Psychological bulletin*. Nov
725 2013;139(6):1221-59. doi:10.1037/a0032247
726 79. Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC, Cercato
727 C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-
728 analysis. *Diabetology & metabolic syndrome*. Apr 24 2024;16(1):92. doi:10.1186/s13098-
729 024-01337-5
730 80. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The
731 multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. *Diabetes*.
732 Dec 2002;51 Suppl 3:S434-42. doi:10.2337/diabetes.51.2007.s434

81. Adams DM, Reay WR, Geaghan MP, Cairns MJ. Investigation of glycaemic traits in psychiatric disorders using Mendelian randomisation revealed a causal relationship with anorexia nervosa. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. May 2021;46(6):1093-1102. doi:10.1038/s41386-020-00847-w

82. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ (Clinical research ed)*. Apr 6 2023;381:e074068. doi:10.1136/bmj-2022-074068

83. Ye CJ, Liu D, Chen ML, et al. Mendelian randomization evidence for the causal effect of mental well-being on healthy aging. *Nature human behaviour*. Jun 17 2024;doi:10.1038/s41562-024-01905-9

84. Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. Dec 2012;32(12):2201-10. doi:10.1038/jcbfm.2012.133

85. Schooling CM, Yang G, Soliman GA, Leung GM. A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK). *Life (Basel)*. Feb 7 2025;15(2)doi:10.3390/life15020253

86. Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug

754 development. *Nature reviews Drug discovery*. Jul 2019;18(7):527-551. doi:10.1038/s41573-
755 019-0019-2
756 87. Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The
757 use of two-sample methods for Mendelian randomization analyses on single large datasets.
758 *International journal of epidemiology*. Apr 26 2021;doi:10.1093/ije/dyab084
759



Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being.

BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.



Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

770 ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

771 hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

772 genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

773 predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

774 or per 1-mmol/mol decrease in HbA1c.

775



Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores. AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented in

782 standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed

783 score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.



Figure 4. Pairwise colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

786 BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional

787 probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with

788 the outcome. Given the presence of a shared variant associated with both traits, the labeled variant had the largest probability of being the shared

789 causal variant.